In addition to its potential role in treatment of T2DM, GLP-1 is also presumed to affect cardiovascular function or cardiovascular disease (CVD) because the GLP-1 receptor has been identified in the heart, kidneys, and blood vessels. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.